Myriad Genetics (MYGN) Tops Q3 EPS by 8c

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $173.1 million versus the consensus estimate of $156.2 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c